What's in Neurocrine Biosciences, Inc.'s pipeline?

Neurocrine Biosciences, Inc. has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Neurocrine Biosciences, Inc.'s portfolio?

Top competitors by shared drug class: Orion Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/neurocrine.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Neurocrine Biosciences, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurocrine Biosciences, Inc. (NBIX) pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

NBIX (NASDAQ) 3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Crenessity	CRINECERFONT	marketed	Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]		Nephrology	2024-01-01
Ongentys	BIA 9-1067	marketed	Catechol-O-Methyltransferase Inhibitor [EPC]	Catechol O-methyltransferase	Metabolic	2020-01-01
Ingrezza	valbenazine	marketed		Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter	Neuroscience

Therapeutic area mix

Metabolic · 1
Nephrology · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

2026-04-08 — Ingrezza · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-07-26 — Ongentys · 9550759 · US
2027-05-12 — Ongentys · 8907099 · US
2027-10-10 — Ongentys · 9745290 · US
2029-04-02 — Ongentys · 8168793 · US
2029-07-14 — Ongentys · 8524746 · US
2030-03-31 — Ongentys · 10071085 · US
2030-03-31 — Ongentys · 10583130 · US
2032-12-12 — Ongentys · 9630955 · US
2035-05-27 — Ongentys · 10357468 · US

Competitive overlap (companies sharing drug classes)

Orion Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neurocrine Biosciences, Inc.:

Cite this brief

Drug Landscape (2026). Neurocrine Biosciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurocrine. Accessed 2026-06-10.